CalciMedica (CALC) 10% Owner ALAFI Capital Receives Warrants

What Happened
ALAFI CAPITAL CO LLC, reported as a 10% owner of CalciMedica, received two derivative awards (warrants) on August 19, 2026: 3,529,192 Series A warrants and 3,529,192 Series B warrants (total 7,058,384 warrants). Each grant was reported at $0.00 acquisition price (i.e., warrants issued, not an open‑market purchase or sale). These are grants of convertible rights (warrants), not direct purchases of common stock.

Key Details

• Transaction date: August 19, 2026; Filing date (Form 4): August 24, 2026 (filed 5 days after transaction — appears late relative to the typical 2-business‑day Form 4 requirement).
• Instrument and amounts: 3,529,192 Series A warrants (F1), 3,529,192 Series B warrants (F3); reported acquisition code A (grant/award). Price reported: $0.00.
• Shares owned after transaction: Not specified in the provided filing details.
• Notable footnotes:
  • F1: Series A Warrants issue date is August 19, 2026.
  • F2: Series A Warrants expire the earlier of (i) 18 months after the private placement closing or (ii) 30 days after the issuer publicly announces FDA clearance of its IND for CM5480.
  • F3: Series B Warrants issue date is August 19, 2026.
• Insider type: ALAFI is a 10% institutional owner, not an individual executive — institutional ownership changes can reflect financing/placement activity rather than executive trading.

Context
Warrants are derivative instruments that may convert into common shares under specified terms; the reported grants do not represent immediate share purchases or sales. The Series A warrants have an unusually conditional/short potential life tied to the private placement timeline and a possible FDA IND clearance event (per F2). Because this is an institutional 10% owner receiving warrants (likely in connection with financing/private placement terms referenced by the footnotes), it should be viewed as capital‑markets activity rather than a direct signal of insider sentiment.